Raidium

Executive Summary

Raidium is a French startup pioneering the first radiological foundation model, described as the 'GPT of radiology.' This AI-native platform enables the creation of an imaging biomarker factory designed to accelerate precision medicine in oncology and radiopharmaceuticals. Founded in 2020 and headquartered in Paris, Raidium aims to transform clinical practice and research by generating novel biomarkers from medical imaging data. The company's approach leverages large-scale, self-supervised learning to capture complex radiological patterns, potentially improving diagnosis, treatment planning, and drug development. While still in early development with no disclosed funding or revenue, Raidium's technology targets a critical need in oncology for non-invasive, reproducible biomarkers. The success of the platform hinges on validation through clinical studies and partnerships with healthcare institutions and pharmaceutical companies. The company's position at the intersection of AI and radiopharmaceuticals offers a unique value proposition but also faces significant regulatory and commercial hurdles common to AI-based diagnostics.

Upcoming Catalysts (preview)

• Q2 2026Publication of proof-of-concept study in peer-reviewed journal60% success
• Q4 2026Strategic partnership with major pharmaceutical company for biomarker discovery40% success
• Q2 2027Series A funding round exceeding $10 million50% success